Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.
Related to this article
ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
Late-Breaking Breast Cancer Data at ESMO 2026 Highlight ADCs and Ribociclib
2
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
3
Geron Halts Phase 3 Imetelstat Trial in Relapsed/Refractory Myelofibrosis
4
Dr Wainberg on RASolute 302: Daraxonrasib Across KRAS Variants
5